Tags

Type your tag names separated by a space and hit enter

Development and validation of a LC-ESI-MS/MS method for the determination of swertiamarin in rat plasma and its application in pharmacokinetics.
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jun 01; 879(19):1653-8.JC

Abstract

A new LC-ESI-MS/MS assay method has been developed and validated for the quantification of swertiamarin, a representative bioactive substance of Swertia plants, in rat plasma using gentiopicroside, an analog of swertiamarin on chemical structure and chromatographic action, as the internal standard (IS). The swertiamarin and IS were extracted from rat plasma using solid-phase extraction (SPE) as the sample clean-up procedure, and they were chromatographed on a narrow internal diameter column (Agilent ZORBAX ECLIPSE XDB-C(18) 100 mm × 2.1 mm, 1.8 μm) with the mobile phase consisting of methanol and water containing 0.1% acetic acid (25:75, v/v) at a flow rate of 0.2 mL/min. The detection was performed on an Agilent G6410B tandem mass spectrometer by negative ion electrospray ionisation in multiple-reaction monitoring mode while monitoring the transitions of m/z 433 [M+CH(3)COO](-)→179 and m/z 415 [M+CH(3)COO](-)→179 for swertiamarin and IS, respectively. The lower limit of quantification (LLOQ) was 5 ng/mL within a linear range of 5-1000 ng/mL (n=7, r(2)≥0.994), and the limit of detection (LOD) was demonstrated as 1.25 ng/mL (S/N≥3). The method also afforded satisfactory results in terms of sensitivity, specificity, precision (intra- and inter-day), accuracy, recovery, freeze/thaw, long-time stability and dilution integrity. This method was successfully applied to determination of the pharmacokinetic properties of swertiamarin in rats after oral administration at a dose of 20 mg/kg. The following pharmacokinetic parameters were obtained (mean): maximum plasma concentration, 1920.1 ng/mL; time to reach maximum plasma concentration, 0.945 h; elimination half-time, 1.10h; apparent total clearance, 5.638 L/h/kg; and apparent volume of distribution, 9.637 L/kg.

Authors+Show Affiliations

Department of Pharmacy, Kunming General Hospital of Chengdu Military Region, Kunming, PR China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21531636

Citation

Li, Hong-Liang, et al. "Development and Validation of a LC-ESI-MS/MS Method for the Determination of Swertiamarin in Rat Plasma and Its Application in Pharmacokinetics." Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, vol. 879, no. 19, 2011, pp. 1653-8.
Li HL, Peng XJ, He JC, et al. Development and validation of a LC-ESI-MS/MS method for the determination of swertiamarin in rat plasma and its application in pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(19):1653-8.
Li, H. L., Peng, X. J., He, J. C., Feng, E. F., Xu, G. L., & Rao, G. X. (2011). Development and validation of a LC-ESI-MS/MS method for the determination of swertiamarin in rat plasma and its application in pharmacokinetics. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 879(19), 1653-8. https://doi.org/10.1016/j.jchromb.2011.04.003
Li HL, et al. Development and Validation of a LC-ESI-MS/MS Method for the Determination of Swertiamarin in Rat Plasma and Its Application in Pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jun 1;879(19):1653-8. PubMed PMID: 21531636.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development and validation of a LC-ESI-MS/MS method for the determination of swertiamarin in rat plasma and its application in pharmacokinetics. AU - Li,Hong-Liang, AU - Peng,Xiao-Jin, AU - He,Jian-Chang, AU - Feng,En-Fu, AU - Xu,Gui-Li, AU - Rao,Gao-Xiong, Y1 - 2011/04/12/ PY - 2010/12/10/received PY - 2011/03/31/revised PY - 2011/04/04/accepted PY - 2011/5/3/entrez PY - 2011/5/3/pubmed PY - 2011/9/8/medline SP - 1653 EP - 8 JF - Journal of chromatography. B, Analytical technologies in the biomedical and life sciences JO - J Chromatogr B Analyt Technol Biomed Life Sci VL - 879 IS - 19 N2 - A new LC-ESI-MS/MS assay method has been developed and validated for the quantification of swertiamarin, a representative bioactive substance of Swertia plants, in rat plasma using gentiopicroside, an analog of swertiamarin on chemical structure and chromatographic action, as the internal standard (IS). The swertiamarin and IS were extracted from rat plasma using solid-phase extraction (SPE) as the sample clean-up procedure, and they were chromatographed on a narrow internal diameter column (Agilent ZORBAX ECLIPSE XDB-C(18) 100 mm × 2.1 mm, 1.8 μm) with the mobile phase consisting of methanol and water containing 0.1% acetic acid (25:75, v/v) at a flow rate of 0.2 mL/min. The detection was performed on an Agilent G6410B tandem mass spectrometer by negative ion electrospray ionisation in multiple-reaction monitoring mode while monitoring the transitions of m/z 433 [M+CH(3)COO](-)→179 and m/z 415 [M+CH(3)COO](-)→179 for swertiamarin and IS, respectively. The lower limit of quantification (LLOQ) was 5 ng/mL within a linear range of 5-1000 ng/mL (n=7, r(2)≥0.994), and the limit of detection (LOD) was demonstrated as 1.25 ng/mL (S/N≥3). The method also afforded satisfactory results in terms of sensitivity, specificity, precision (intra- and inter-day), accuracy, recovery, freeze/thaw, long-time stability and dilution integrity. This method was successfully applied to determination of the pharmacokinetic properties of swertiamarin in rats after oral administration at a dose of 20 mg/kg. The following pharmacokinetic parameters were obtained (mean): maximum plasma concentration, 1920.1 ng/mL; time to reach maximum plasma concentration, 0.945 h; elimination half-time, 1.10h; apparent total clearance, 5.638 L/h/kg; and apparent volume of distribution, 9.637 L/kg. SN - 1873-376X UR - https://www.unboundmedicine.com/medline/citation/21531636/Development_and_validation_of_a_LC_ESI_MS/MS_method_for_the_determination_of_swertiamarin_in_rat_plasma_and_its_application_in_pharmacokinetics_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1570-0232(11)00240-6 DB - PRIME DP - Unbound Medicine ER -